Read on Twitter
On this week's #Urixnrk, @msfnorge and I discussed vaccine politics, global solidarity and the imperative that vaccine producers like @pfizer @moderna_tx & @AstraZeneca urgently contribute to equitable global access. The question is, how? 
https://tv.nrk.no/serie/urix/202102/NNFA53021021/avspiller
https://tv.nrk.no/serie/urix/202102/NNFA53021021/avspiller
In @ForeignAffairs @realtahiramin says wealthy countries who have hoarded vaccine doses now must either support #tripswaiver or require pharma to enter into technology transfer agreements with global south suppliers, or both https://www.foreignaffairs.com/articles/world/2021-01-29/folly-hoarding-knowledge-covid-19-age
Based on view that suspending patent rights now is unfeasible, ACT-A co-chair Norway has issued “principles” to @wef for urgent pharma action on rapid registration, fair pricing, expanded production capacity and greater transparency. https://www.weforum.org/agenda/2021/02/4-principles-pharma-action-combat-covid19/.
But will such appeals to greater cooperation work? How will @ACTAccelerator and @covaxxvaccine convince pharma companies to abide by voluntary principles? What power lies behind these demands?
Norway’s Global Health Ambassador @jarottingen says he and ACT-A co-chair @dagiulstein are working on how to ensure pharma steps up to these principles, and would like (feasible) ideas. Anyone?
